Physician profile
Princess Maria Curtis
NPI 1063678944
$2,477.99
in general payments reported to CMS, 2019-2025
19 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.79 · 2020: $11.40 · 2023: $138 · 2024: $1,117 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332 · Education: $97.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.10 |
| Education | $97.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.29 | 2019-2025 | Rinvoq |
| Amgen INC. | $421.37 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $231.26 | 2024-2025 | Ebglyss, Taltz, Zepbound |
| Janssen Biotech, INC. | $177.65 | 2024-2025 | Tremfya |
| Pfizer INC. | $158.09 | 2024-2025 | |
| Incyte Corporation | $152.34 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $119.05 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $114.62 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $85.80 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $79.90 | 2020-2025 | Anzupgo, Adbry |
| Mayne Pharma Commercial LLC | $70.67 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $69.06 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $61.52 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $45.91 | 2024-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.44 | 2024-2025 | Cabtreo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $15.82 | 2025 | Zelsuvmi |
| Ucb, INC. | $15.13 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.93 | 2024 | Spevigo |
| Organon LLC | $6.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Princess Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.